Trials / Completed
CompletedNCT00349193
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions. The duration of the current study is 36 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | laquinimod 0.3 | laquinimod 0.3mg |
| DRUG | laquinimod 0.6 | laquinimod 0.6mg |
| OTHER | Placebo | Blinded Placebo |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2006-06-01
- Completion
- 2006-08-01
- First posted
- 2006-07-06
- Last updated
- 2011-04-08
Source: ClinicalTrials.gov record NCT00349193. Inclusion in this directory is not an endorsement.